Transconjunctival immunotherapy using cholera toxin B to treat experimental allergic conjunctivitis in a mouse model

2011 ◽  
Vol 55 (5) ◽  
pp. 534-540
Author(s):  
Aki Oikawa ◽  
Jun Shoji ◽  
Noriko Inada ◽  
Mitsuru Sawa
Keyword(s):  
Mouse Model ◽  
Cholera Toxin ◽  
Allergic Conjunctivitis ◽  
Toxin B ◽  
Cholera Toxin B ◽  
Experimental Allergic

scholarly journals Immunization with Cholera Toxin B Subunit Induces High-Level Protection in the Suckling Mouse Model of Cholera

PLoS ONE ◽  
2013 ◽  
Vol 8 (2) ◽  
pp. e57269 ◽  
Author(s):  
Gregory A. Price ◽  
Kim McFann ◽  
Randall K. Holmes
Keyword(s):  
Mouse Model ◽  
Cholera Toxin ◽  
Cholera Toxin B Subunit ◽  
Suckling Mouse ◽  
Toxin B ◽  
Cholera Toxin B ◽  
B Subunit ◽  
High Level

scholarly journals Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse model

2010 ◽  
Vol 59 (12) ◽  
pp. 1801-1811 ◽  
Author(s):  
Julia Pinkhasov ◽  
M. Lucrecia Alvarez ◽  
Latha B. Pathangey ◽  
Teresa L. Tinder ◽  
Hugh S. Mason ◽  
...  
Keyword(s):  
Mouse Model ◽  
Cholera Toxin ◽  
Cholera Toxin B Subunit ◽  
Mucin 1 ◽  
Toxin B ◽  
Cholera Toxin B ◽  
B Subunit ◽  
Tolerant Mouse

scholarly journals Immunogenicity and protective efficacy of rotavirus VP8*fused to cholera toxin B subunit in a mouse model

2016 ◽  
Vol 12 (11) ◽  
pp. 2959-2968 ◽  
Author(s):  
Miaoge Xue ◽  
Linqi Yu ◽  
Lianzhi Jia ◽  
Yijian Li ◽  
Yuanjun Zeng ◽  
...  
Keyword(s):  
Mouse Model ◽  
Cholera Toxin ◽  
Protective Efficacy ◽  
Cholera Toxin B Subunit ◽  
Toxin B ◽  
Cholera Toxin B ◽  
B Subunit

Purification and Analysis of a Recombinant Human Anti-Cholera Toxin B Antibody.

1998 ◽  
Author(s):  
Jessica Dang ◽  
Suzanne Kracke ◽  
Peter A. Emanuel ◽  
Michael J. Gostomski ◽  
Darrel E. Menking
Keyword(s):  
Cholera Toxin ◽  
Toxin B ◽  
Cholera Toxin B

scholarly journals Spray-Dried Formulation of Epicertin, a Recombinant Cholera Toxin B Subunit Variant That Induces Mucosal Healing

Pharmaceutics ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 576
Author(s):  
Micaela A. Reeves ◽  
Joshua M. Royal ◽  
David A. Morris ◽  
Jessica M. Jurkiewicz ◽  
Nobuyuki Matoba ◽  
...  
Keyword(s):  
Gastric Acid ◽  
Cholera Toxin ◽  
Oral Formulation ◽  
Size Exclusion ◽  
Cholera Toxin B Subunit ◽  
Toxin B ◽  
Cholera Toxin B ◽  
B Subunit ◽  
Enteric Coated ◽  
Spray Dried

Epicertin (EPT) is a recombinant variant of the cholera toxin B subunit, modified with a C-terminal KDEL endoplasmic reticulum retention motif. EPT has therapeutic potential for ulcerative colitis treatment. Previously, orally administered EPT demonstrated colon epithelial repair activity in dextran sodium sulfate (DSS)-induced acute and chronic colitis in mice. However, the oral dosing requires cumbersome pretreatment with sodium bicarbonate to conserve the acid-labile drug substance while transit through the stomach, hampering its facile application in chronic disease treatment. Here, we developed a solid oral formulation of EPT that circumvents degradation in gastric acid. EPT was spray-dried and packed into enteric-coated capsules to allow for pH-dependent release in the colon. A GM1-capture KDEL-detection ELISA and size-exclusion HPLC indicated that EPT powder maintains activity and structural stability for up to 9 months. Capsule disintegration tests showed that EPT remained encapsulated at pH 1 but was released over 180 min at pH 6.8, the approximate pH of the proximal colon. An acute DSS colitis study confirmed the therapeutic efficacy of encapsulated EPT in C57BL/6 mice upon oral administration without gastric acid neutralization pretreatment compared to vehicle-treated mice (p < 0.05). These results provide a foundation for an enteric-coated oral formulation of spray-dried EPT.

Sign in / Sign up

Export Citation Format

Share Document